Wyszuk. zaawans.

Tom 18, Nr 2 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-09-02
Dodaj do koszyka: 49,00 PLN
Wyświetlenia strony 3251
Wyświetlenia/pobrania artykułu 40
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Naturalne inhibitory PCSK9 — przegląd substancji o możliwym wpływie na PCSK9

Stanisław Surma12, Krzysztof J. Filipiak3
DOI: 10.5603/ChSiN.2021.0007
Choroby Serca i Naczyń 2021;18(2):60-76.

Streszczenie

Proproteinowa konwertaza subtilizyny/kexiny typu 9 (PCSK9) jest białkiem odkrytym w 2003 roku i pełniącym istotną rolę w metabolizmie lipoprotein. Główną funkcją PCSK9 jest regulacja liczby receptorów dla lipoprotein o niskiej gęstości (LDL) na powierzchni hepatocytów. Efektem biologicznym PSCK9 jest zmniejszenie liczby receptorów LDL na powierzchni hepatocytów, co ogranicza ich zdolność do wychwytywania lipoprotein LDL. Inhibitory PCSK9, takie jak alirokumab, ewolokumab czy inklisiran, stanowią nową, bardzo skuteczną metodę terapii hipolipemizującej. W ostatnim czasie zidentyfikowano szereg związków pochodzenia naturalnego, które charakteryzują się zdolnością do zmniejszania aktywności PCSK9. Związki te należą do alkaloidów, polifenoli, steroli, stanoli, białek występujących w warzywach oraz innych składników odżywczych i mogą znaleźć zastosowanie we wspomaganiu farmakoterapii zaburzeń lipidowych.

Słowa kluczowe: inhibitory PCSK9 pochodzenia naturalnegochoroby układu krążenia

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA. 2005; 102(6): 2069–2074.
    CrossRefPubMed
  2. Momtazi AA, Banach M, Pirro M, et al. Regulation of PCSK9 by nutraceuticals. Pharmacol Res. 2017; 120: 157–169.
    CrossRefPubMed
  3. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003; 100(3): 928–933.
    CrossRefPubMed
  4. Tavori H, Christian D, Minnier J, et al. PCSK9 association with lipoprotein(a). Circ Res. 2016; 119(1): 29–35.
    CrossRefPubMed
  5. Ruscica M, Simonelli S, Botta M, et al. Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1863(9): 991–997.
    CrossRefPubMed
  6. Macchi C, Banach M, Corsini A, et al. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels — experimental and clinical approaches with lipid-lowering agents. Eur J Prev Cardiol. 2019; 26(9): 930–949.
    CrossRefPubMed
  7. Awan Z, Baass A, Genest J. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia. Clin Chem. 2014; 60(11): 1380–1389.
    CrossRefPubMed
  8. Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009; 284(42): 28856–28864.
    CrossRefPubMed
  9. Qian YW, Schmidt RJ, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res. 2007; 48(7): 1488–1498.
    CrossRefPubMed
  10. Adorni MP, Zimetti F, Lupo M, et al. Naturally occurring PCSK9 inhibitors. Nutrients. 2020; 12(5): 1440.
    CrossRef
  11. Goldstein JL, Brown MS, Anderson RG, et al. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol. 1985; 1: 1–39.
    CrossRefPubMed
  12. Horton JD, Shah NA, Warrington JA, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA. 2003; 100(21): 12027–12032.
    CrossRefPubMed
  13. Nozue T. Lipid lowering therapy and circulating PCSK9 concentration. J Atheroscler Thromb. 2017; 24(9): 895–907.
    CrossRefPubMed
  14. Schulz R, Schlüter KD, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol. 2015; 110(2): 4.
    CrossRefPubMed
  15. Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009; 284(42): 28885–28895.
    CrossRefPubMed
  16. Dong H, Wang N, Zhao Li, et al. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med. 2012; 2012: 591654.
    CrossRefPubMed
  17. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015; 161: 69–81.
    CrossRefPubMed
  18. Wang L, Ye X, Hua Y, et al. Berberine alleviates adipose tissue fibrosis by inducing AMP-activated kinase signaling in high-fat diet-induced obese mice. Biomed Pharmacother. 2018; 105: 121–129.
    CrossRefPubMed
  19. Andola HC, Gaira KS, Rawal RS, et al. Habitat-dependent variations in berberine content of Berberis asiatica Roxb. ex. DC. in Kumaon, Western Himalaya. Chem Biodivers. 2010; 7(2): 415–420.
    CrossRefPubMed
  20. Cameron J, Ranheim T, Kulseth MA, et al. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008; 201(2): 266–273.
    CrossRefPubMed
  21. Xiao HB, Sun ZL, Zhang HB, et al. Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. Pharmacol Rep. 2012; 64(4): 889–895.
    CrossRefPubMed
  22. Liu Dl, Xu Lj, Dong H, et al. Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia. Chin J Integr Med. 2015; 21(2): 132–138.
    CrossRefPubMed
  23. Adorni MP, Ferri N, Marchianò S, et al. Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9. Ther Clin Risk Manag. 2017; 13: 1555–1562.
    CrossRefPubMed
  24. Spigoni V, Aldigeri R, Antonini M, et al. Effects of a new nutraceutical formulation (berberine, red yeast rice and chitosan) on non-HDL cholesterol levels in individuals with dyslipidemia: results from a randomized, double blind, placebo-controlled study. Int J Mol Sci. 2017; 18: 1498.
  25. Formisano E, Pasta A, Cremonini AL, et al. Efficacy of Nutraceutical Combination of Monacolin K, Berberine, and Silymarin on Lipid Profile and PCSK9 Plasma Level in a Cohort of Hypercholesterolemic Patients. J Med Food. 2020; 23(6): 658–666.
    CrossRefPubMed
  26. Pisciotta L, Bellocchio A, Bertolini S. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids Health Dis. 2012; 11: 123.
    CrossRefPubMed
  27. Dong B, Li H, Singh AB, et al. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem. 2015; 290(7): 4047–4058.
    CrossRefPubMed
  28. Dong H, Zhao Y, Zhao Li, et al. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013; 79(6): 437–446.
    CrossRefPubMed
  29. Guo Y, Chen Y, Tan ZR, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012; 68(2): 213–217.
    CrossRefPubMed
  30. De Smet E, Mensink RP, Konings M, et al. Acute intake of plant stanol esters induces changes in lipid and lipoprotein metabolism-related gene expression in the liver and intestines of mice. Lipids. 2015; 50(6): 529–541.
    CrossRefPubMed
  31. Simonen P, Stenman UH, Gylling H. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study. Clin Sci (Lond). 2015; 129(5): 439–446.
    CrossRefPubMed
  32. Lammi C, Zanoni C, Scigliuolo GM, et al. Lupin peptides lower low-density lipoprotein (LDL) cholesterol through an up-regulation of the LDL receptor/sterol regulatory element binding protein 2 (SREBP2) pathway at HepG2 cell line. J Agric Food Chem. 2014; 62(29): 7151–7159.
    CrossRefPubMed
  33. Sirtori CR, Lovati MR, Manzoni C, et al. Proteins of white lupin seed, a naturally isoflavone-poor legume, reduce cholesterolemia in rats and increase LDL receptor activity in HepG2 cells. J Nutr. 2004; 134(1): 18–23.
    CrossRefPubMed
  34. Lammi C, Zanoni C, Calabresi L, et al. Lupin protein exerts cholesterol-lowering effects targeting PCSK9: from clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells. Journal of Functional Foods. 2016; 23: 230–240.
    CrossRef
  35. Pavanello C, Lammi C, Ruscica M, et al. Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients: A randomised controlled trial. Journal of Functional Foods. 2017; 37: 8–15.
    CrossRef
  36. Lammi C, Zanoni C, Aiello G, et al. Lupin peptides modulate the protein-protein interaction of PCSK9 with the low density lipoprotein receptor in HepG2 cells. Sci Rep. 2016; 6: 29931.
    CrossRefPubMed
  37. Ruscica M, Pavanello C, Gandini S, et al. Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial. Eur J Nutr. 2018; 57(2): 499–511.
    CrossRefPubMed
  38. Durazzo A, Lucarini M, Souto EB, et al. Polyphenols: a concise overview on the chemistry, occurrence, and human health. Phytother Res. 2019; 33(9): 2221–2243.
    CrossRefPubMed
  39. Mbikay M, Sirois F, Simoes S, et al. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. FEBS Open Bio. 2014; 4: 755–762.
    CrossRefPubMed
  40. Li S, Cao H, Shen D, et al. Quercetin protects against ox‑LDL‑induced injury via regulation of ABCAl, LXR‑α and PCSK9 in RAW264.7 macrophages. Mol Med Rep. 2018; 18(1): 799–806.
    CrossRefPubMed
  41. Adorni MP, Cipollari E, Favari E, et al. Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis. 2017; 256: 1–6.
    CrossRefPubMed
  42. Ricci C, Ruscica M, Camera M, et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep. 2018; 8(1): 2267.
    CrossRefPubMed
  43. Jia Q, Cao H, Shen D, et al. Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1. Int J Mol Med. 2019; 44(3): 893–902.
    CrossRefPubMed
  44. Kitamura K, Okada Y, Okada K, et al. Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells. Mol Nutr Food Res. 2017; 61(8).
    CrossRefPubMed
  45. Jing Yi, Hu T, Lin C, et al. Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor α-mediated pathway in L02 cells. Eur J Pharmacol. 2019; 855: 216–226.
    CrossRefPubMed
  46. Li Li, Shen C, Huang YX, et al. A new strategy for rapidly screening natural inhibitors targeting the PCSK9/LDLR interaction in vitro. Molecules. 2018; 23(9).
    CrossRefPubMed
  47. Wang Yu, Ye J, Li J, et al. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9). Cardiovasc Diabetol. 2016; 15: 19.
    CrossRefPubMed
  48. Dong Z, Zhang W, Chen S, et al. Silibinin A decreases statin‑induced PCSK9 expression in human hepatoblastoma HepG2 cells. Mol Med Rep. 2019; 20(2): 1383–1392.
    CrossRefPubMed
  49. Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet. 1990; 15(4): 333–338.
    CrossRefPubMed
  50. Sui GG, Xiao HB, Lu XY, et al. Naringin activates AMPK resulting in altered expression of SREBPs, PCSK9, and LDLR to reduce body weight in obese C57BL/6J mice. J Agric Food Chem. 2018; 66(34): 8983–8990.
    CrossRefPubMed
  51. Gao WY, Chen PY, Chen SF, et al. Pinostrobin inhibits proprotein convertase subtilisin/kexin-type 9 (PCSK9) gene expression through the modulation of FoxO3a protein in HepG2 cells. J Agric Food Chem. 2018; 66(24): 6083–6093.
    CrossRefPubMed
  52. Zia S, Batool S, Shahid R. Could PCSK9 be a new therapeutic target of eugenol? In vitro and in silico evaluation of hypothesis. Med Hypotheses. 2020; 136: 109513.
    CrossRefPubMed
  53. Jo HK, Kim GoW, Jeong KJu, et al. Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway. Biol Pharm Bull. 2014; 37(8): 1341–1351.
    CrossRefPubMed
  54. Tai MH, Chen PK, Chen PY, et al. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Mol Nutr Food Res. 2014; 58(11): 2133–2145.
    CrossRefPubMed
  55. Cai Yu, Lu Di, Zou Y, et al. Curcumin protects against intestinal origin endotoxemia in rat liiver cirrhosis by targeting PCSK9. J Food Sci. 2017; 82(3): 772–780.
    CrossRefPubMed
  56. Choi HK, Hwang JT, Nam TG, et al. Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells. Food Funct. 2017; 8(12): 4582–4591.
    CrossRefPubMed
  57. Sung YY, Yoon T, Kim SJu, et al. Anti-obesity activity of Allium fistulosum L. extract by down-regulation of the expression of lipogenic genes in high-fat diet-induced obese mice. Mol Med Rep. 2011; 4(3): 431–435.
    CrossRefPubMed
  58. Baer DJ, Novotny JA. Consumption of cashew nuts does not influence blood lipids or other markers of cardiovascular disease in humans: a randomized controlled trial. Am J Clin Nutr. 2019; 109(2): 269–275.
    CrossRefPubMed
  59. Chan KW, Ismail M, Mohd Esa N, et al. Dietary supplementation of defatted kenaf (Hibiscus cannabinus L.) seed meal and its phenolics-saponins rich extract effectively attenuates diet-induced hypercholesterolemia in rats. Food Funct. 2018; 9(2): 925–936.
    CrossRefPubMed
  60. van Ballegooijen AJ, Beulens JW. The role of vitamin K status in cardiovascular health: evidence from observational and clinical studies. Curr Nutr Rep. 2017; 6(3): 197–205.
    CrossRefPubMed
  61. Lupo MG, Biancorosso N, Brilli E, et al. Cholesterol-lowering action of a novel nutraceutical combination in uremic rats: insights into the molecular mechanism in a hepatoma cell line. Nutrients. 2020; 12(2).
    CrossRefPubMed
  62. Alvi SS, Ansari I, Khan I, et al. Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia. Free Radic Boil. 2017; 108: 394–403.
    CrossRefPubMed
  63. Alvi SS, Ansari IA, Ahmad MK, et al. Lycopene amends LPS induced oxidative stress and hypertriglyceridemia via modulating PCSK-9 expression and Apo-CIII mediated lipoprotein lipase activity. Biomed Pharmacother. 2017; 96: 1082–1093.
    CrossRefPubMed
  64. Chang CL, Deckelbaum RJ. Omega-3 fatty acids: mechanisms underlying 'protective effects' in atherosclerosis. Curr Opin Lipidol. 2013; 24(4): 345–350.
    CrossRefPubMed
  65. Yuan F, Wang H, Tian Yu, et al. Fish oil alleviated high-fat diet-induced non-alcoholic fatty liver disease via regulating hepatic lipids metabolism and metaflammation: a transcriptomic study. Lipids Health Dis. 2016; 15: 20.
    CrossRefPubMed
  66. Sorokin AV, Yang ZH, Vaisman BL, et al. Addition of aspirin to a fish oil-rich diet decreases inflammation and atherosclerosis in ApoE-null mice. J Nutr Biochem. 2016; 35: 58–65.
    CrossRefPubMed
  67. Rodríguez-Pérez C, Ramprasath VR, Pu S, et al. Docosahexaenoic acid attenuates cardiovascular risk factors via a decline in proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma levels. Lipids. 2016; 51(1): 75–83.
    CrossRefPubMed
  68. Bjermo H, Iggman D, Kullberg J, et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr. 2012; 95(5): 1003–1012.
    CrossRefPubMed
  69. Jump DB, Jump DB, Botolin D, et al. Polyunsaturated fatty acid regulation of hepatic gene transcription. Lipids. 1996; 31(Suppl): S7–S11.
    CrossRefPubMed
  70. Graversen CB, Lundbye-Christensen S, Thomsen B, et al. Marine n-3 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre- and postmenopausal women: A randomised study. Vascul Pharmacol. 2016; 76: 37–41.
    CrossRefPubMed
  71. Kourimate S, Le May C, Langhi C, et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem. 2008; 283(15): 9666–9673.
    CrossRefPubMed
  72. Lambert G, Jarnoux AL, Pineau T, et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology. 2006; 147(10): 4985–4995.
    CrossRefPubMed
  73. Mann GV. Studies of a surfactant and cholesteremia in the Maasai. Am J Clin Nutr. 1974; 27(5): 464–469.
    CrossRefPubMed
  74. Ruscica M, Pavanello C, Gandini S, et al. aceutical approach for the management of cardiovascular risk — a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: Results from a randomized, double-blind, placebo-controlled study. Nutr J. 2019; 18(1): 13.
    CrossRefPubMed
  75. Qu L, Li D, Gao X, et al. Di'ao Xinxuekang Capsule, a Chinese medicinal product, decreases serum lipids levels in high-fat diet-fed ApoE-/- mice by downregulating PCSK9. Front Pharmacol. 2018; 9: 1170.
    CrossRefPubMed
  76. Gai Y, Li Y, Xu Z, et al. Pseudoprotodioscin inhibits SREBPs and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides. Fitoterapia. 2019; 139: 104393.
    CrossRefPubMed
  77. Li J, Ding L, Song B, et al. Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP pathway. Eur J Pharmacol. 2016; 770: 99–109.
    CrossRefPubMed
  78. Su ZL, Hang PZ, Hu J, et al. Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats. Acta Pharmacol Sin. 2020; 41(8): 1085–1092.
    CrossRefPubMed
  79. Yang JiH, Bang MiAe, Jang CHo, et al. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression. J Nutr Biochem. 2015; 26(11): 1393–1400.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice